BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46:286-294. [PMID: 17166617 DOI: 10.1016/j.jhep.2006.08.023] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: Coagulation and hepatic fibrogenesis. Clin Liver Dis. 2009;13:117-126. [PMID: 19150316 DOI: 10.1016/j.cld.2008.09.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
2 Liu J, Tan H, Sun Y, Zhou S, Cao J, Wang F. The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol Cell Biochem 2009;327:219-28. [PMID: 19242656 DOI: 10.1007/s11010-009-0060-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
3 Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology 2008;47:1384-93. [DOI: 10.1002/hep.22192] [Cited by in Crossref: 77] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
4 Hosoya S, Ikejima K, Takeda K, Arai K, Ishikawa S, Yamagata H, Aoyama T, Kon K, Yamashina S, Watanabe S. Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice. Am J Physiol Gastrointest Liver Physiol. 2013;304:G293-G299. [PMID: 23086918 DOI: 10.1152/ajpgi.00083.2012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
5 Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S. Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology. 2009;49:1636-1644. [PMID: 19205029 DOI: 10.1002/hep.22828] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
6 Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61:1721-1727. [PMID: 26725062 DOI: 10.1007/s10620-015-4012-2] [Cited by in Crossref: 135] [Cited by in F6Publishing: 101] [Article Influence: 27.0] [Reference Citation Analysis]
7 Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 2008;13:2758-85. [PMID: 19002078 DOI: 10.3390/molecules13112758] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
8 Davis JPE, Caldwell SH. Healing gone wrong: convergence of hemostatic pathways and liver fibrosis? Clin Sci (Lond) 2020;134:2189-201. [PMID: 32844997 DOI: 10.1042/CS20191102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Atanasova I, Sojoodi M, Leitão HS, Shuvaev S, Geraldes CFGC, Masia R, Guimaraes AS, Tanabe KK, Fuchs BC, Caravan P. Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. Invest Radiol 2020;55:209-16. [PMID: 31895219 DOI: 10.1097/RLI.0000000000000631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
10 Fortea JI, Puente Á, Cuadrado A, Huelin P, Pellón R, González Sánchez FJ, Mayorga M, Cagigal ML, García Carrera I, Cobreros M, Crespo J, Fábrega E. Congestive Hepatopathy. Int J Mol Sci 2020;21:E9420. [PMID: 33321947 DOI: 10.3390/ijms21249420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kukner A, Tore F, Firat T, Terzi EH, Oner H, Balaban YH, Ozogul C. The preventive effect of low molecular weight heparin on CCL4-induced necrosis and apoptosis in rat liver. Annals of Hepatology 2010;9:445-54. [DOI: 10.1016/s1665-2681(19)31621-7] [Cited by in Crossref: 15] [Article Influence: 1.4] [Reference Citation Analysis]
12 Ponziani FR, Zocco MA, Garcovich M, D'Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World J Gastroenterol. 2012;18:5014-5020. [PMID: 23049208 DOI: 10.3748/wjg.v18.i36.5014] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
13 Intagliata NM, Maitland H, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14:247-256. [PMID: 27020266 DOI: 10.1007/s11938-016-0092-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
14 Plompen EP, Schouten JN, Janssen HL. Role of anticoagulant therapy in liver disease. Hepatol Int. 2013;7:369-376. [PMID: 26201771 DOI: 10.1007/s12072-013-9427-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2018;315:G171-6. [PMID: 29723040 DOI: 10.1152/ajpgi.00402.2017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost. 2016;14:1337-1349. [PMID: 27060337 DOI: 10.1111/jth.13327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Yan Y, Ji Y, Su N, Mei X, Wang Y, Du S, Zhu W, Zhang C, Lu Y, Xing XH. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review. Carbohydr Polym 2017;160:71-81. [PMID: 28115102 DOI: 10.1016/j.carbpol.2016.12.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
18 Cafolla A, Gentile G. Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report. Clin Case Rep 2017;5:342-5. [PMID: 28265403 DOI: 10.1002/ccr3.820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hu D, Jiang J, Lin Z, Zhang C, Moonasar N, Qian S. Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis. Int J Med Sci 2021;18:1554-65. [PMID: 33746571 DOI: 10.7150/ijms.52846] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lisman T. Platelets and fibrin in progression of liver disease: friends or foes? J Thromb Haemost. 2015;13:54-56. [PMID: 25393399 DOI: 10.1111/jth.12783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
21 Shimizu S, Saito M, Oiwa H, Ohmasa F, Tsounapi P, Oikawa R, Dimitriadis F, Martin DT, Satoh I, Kinoshita Y, Tomita S. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress: Olmesartan Ameliorates Bladder Dysfunction. Neurourol Urodynam 2014;33:350-7. [DOI: 10.1002/nau.22405] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
22 Guerrero JA, Teruel R, Martínez C, Arcas I, Martínez-Martínez I, de la Morena-Barrio ME, Vicente V, Corral J. Protective role of antithrombin in mouse models of liver injury. J Hepatol 2012;57:980-6. [PMID: 22749941 DOI: 10.1016/j.jhep.2012.06.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
23 Poujol-Robert A, Boëlle PY, Conti F, Durand F, Duvoux C, Wendum D, Paradis V, Mackiewicz V, Chazouillères O, Corpechot C. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clin Res Hepatol Gastroenterol. 2014;38:570-576. [PMID: 25130796 DOI: 10.1016/j.clinre.2014.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
24 Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148-154. [PMID: 24657400 DOI: 10.1016/j.jhep.2014.03.013] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 12.1] [Reference Citation Analysis]
25 Greuter T, Shah VH. Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol. 2016;51:511-519. [PMID: 26939970 DOI: 10.1007/s00535-016-1190-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
26 Qian Y, Li L, Song Y, Dong L, Chen P, Li X, Cai K, Germershaus O, Yang L, Fan Y. Surface modification of nanofibrous matrices via layer-by-layer functionalized silk assembly for mitigating the foreign body reaction. Biomaterials 2018;164:22-37. [DOI: 10.1016/j.biomaterials.2018.02.038] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
27 Simonetto DA, Yang HY, Yin M, de Assuncao TM, Kwon JH, Hilscher M, Pan S, Yang L, Bi Y, Beyder A. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatology. 2015;61:648-659. [PMID: 25142214 DOI: 10.1002/hep.27387] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 15.2] [Reference Citation Analysis]
28 Marques TG, Chaib E, da Fonseca JH, Lourenço AC, Silva FD, Ribeiro MA Jr, Galvão FH, D'Albuquerque LA. Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras 2012;27:589-94. [PMID: 22850713 DOI: 10.1590/s0102-86502012000800013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
29 Yukawa H, Noguchi H, Oishi K, Takagi S, Hamaguchi M, Hamajima N, Hayashi S. Cell Transplantation of Adipose Tissue-Derived Stem Cells in Combination with Heparin Attenuated Acute Liver Failure in Mice. Cell Transplant 2009;18:611-8. [DOI: 10.1177/096368970901805-617] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
30 Cui C, Wei P, Liu Y, Zhang D, Wang L, Wu C. The protective role of Hepatopoietin Cn on liver injury induced by carbon tetrachloride in rats. Hepatology Research 2009;39:200-6. [DOI: 10.1111/j.1872-034x.2008.00447.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
31 Turco L, Schepis F, Villa E. The Role of Anticoagulation in Treating Portal Hypertension. Curr Hepatol Rep 2018;17:200-8. [PMID: 30546994 DOI: 10.1007/s11901-018-0406-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Lentschener C, Flaujac C, Ibrahim F, Gouin-Thibault I, Bazin M, Sogni P, Samama CM. Assessment of haemostasis in patients with cirrhosis: Relevance of the ROTEM tests?: A prospective, cross-sectional study. Eur J Anaesthesiol 2016;33:126-33. [PMID: 26258657 DOI: 10.1097/EJA.0000000000000322] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
33 Chen H, Liu L, Qi X, He C, Wu F, Fan D, Han G. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:82-89. [PMID: 26513611 DOI: 10.1097/meg.0000000000000482] [Cited by in Crossref: 60] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
34 Yang ZJ, Costa KA, Novelli EM, Smith RE. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost 2014;20:169-78. [PMID: 23076776 DOI: 10.1177/1076029612461846] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
35 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878-885. [PMID: 20400681 DOI: 10.1182/blood-2010-02-261891] [Cited by in Crossref: 357] [Cited by in F6Publishing: 269] [Article Influence: 32.5] [Reference Citation Analysis]
36 Saito T, Tabata Y. Preparation of gelatin hydrogels incorporating low-molecular-weight heparin for anti-fibrotic therapy. Acta Biomaterialia 2012;8:646-52. [DOI: 10.1016/j.actbio.2011.10.025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
37 Liu J, Teng L, Liu C, Hu L, Wang Y, Liu H, Wang F. Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by chemical modification with polysaccharide and attenuation effects on radiation-induced inflammatory cytokine expression in vitro. Journal of Drug Targeting 2009;17:216-24. [DOI: 10.1080/10611860802669249] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
38 Li L, Yang Y, Zhang Z, Nie S, Li Z, Li F, Hua H, Hu Y, Zhang H, Guo Y. Protective effects of medical ozone combined with traditional Chinese medicine against chemically-induced hepatic injury in dogs. WJG 2007;13:5989. [DOI: 10.3748/wjg.v13.45.5989] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Hugenholtz GC, Northup PG, Porte RJ, Lisman T. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy? Blood Rev. 2015;29:127-136. [PMID: 25468718 DOI: 10.1016/j.blre.2014.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
40 Beyer S, Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG. Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques. Journal of Controlled Release 2016;235:352-64. [DOI: 10.1016/j.jconrel.2016.06.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
41 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Reference Citation Analysis]
42 Poole LG, Pant A, Baker KS, Kopec AK, Cline-Fedewa HM, Iismaa SE, Flick MJ, Luyendyk JP. Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase. J Thromb Haemost 2019;17:113-25. [PMID: 30415489 DOI: 10.1111/jth.14330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Kopec AK, Luyendyk JP. Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association? Semin Thromb Hemost 2016;42:397-407. [PMID: 27144445 DOI: 10.1055/s-0036-1579655] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
44 Poole LG, Pant A, Cline-Fedewa HM, Williams KJ, Copple BL, Palumbo JS, Luyendyk JP. Liver fibrosis is driven by protease-activated receptor-1 expressed by hepatic stellate cells in experimental chronic liver injury. Res Pract Thromb Haemost 2020;4:906-17. [PMID: 32685902 DOI: 10.1002/rth2.12403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Luyendyk J, Roth R, Ganey P. Inflammation and Hepatotoxicity. Comprehensive Toxicology. Elsevier; 2010. pp. 295-317. [DOI: 10.1016/b978-0-08-046884-6.01031-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Hidaka H, Iwakiri Y. Hepatic congestion leads to fibrosis: findings in a newly developed murine model. Hepatology 2015;61:428-30. [PMID: 25283276 DOI: 10.1002/hep.27550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
47 Cerini F, Vilaseca M, Lafoz E, García-Irigoyen O, García-Calderó H, Tripathi DM, Avila M, Reverter JC, Bosch J, Gracia-Sancho J. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016;64:834-842. [PMID: 26686269 DOI: 10.1016/j.jhep.2015.12.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
48 Zakeri N, Tsochatzis EA. Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep. 2017;19:45. [PMID: 28752476 DOI: 10.1007/s11894-017-0585-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
49 Dik K, de Bruijne J, Takkenberg RB, Roelofs JJ, Tempelmans MJ, Dijkgraaf MG, Gelderblom HC, Reesink HW, Meijers JC, Jansen PL. Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. Hepatol Res. 2012;42:668-676. [PMID: 22385348 DOI: 10.1111/j.1872-034x.2011.00963.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
50 Bitto N, Liguori E, La Mura V. Coagulation, Microenvironment and Liver Fibrosis. Cells. 2018;7:pii: E85. [PMID: 30042349 DOI: 10.3390/cells7080085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
51 Isaac O, Thiemer K. Biochemical studies on camomile components/III. In vitro studies about the antipeptic activity of (--)-alpha-bisabolol (author's transl). Arzneimittelforschung. 1975;25:1352-1354. [PMID: 21 DOI: 10.1016/j.clinre.2011.03.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 1.2] [Reference Citation Analysis]
52 Kabra H, Walimbe T, Stuart K, Indey C, Jalgaonkar S, Ikwa E, Skurnac T, Chen J, Woolley A, Snead NM, Bachtell N, Leeming DJ, Karsdal M, Prestwich G, Panitch A, Paderi J. Localized inhibition of platelets and platelet derived growth factor by a matrix targeted glycan mimetic significantly attenuates liver fibrosis. Biomaterials 2021;269:120538. [PMID: 33246740 DOI: 10.1016/j.biomaterials.2020.120538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences1: Hypercoagulability in cirrhosis. Journal of Thrombosis and Haemostasis 2011;9:1713-23. [DOI: 10.1111/j.1538-7836.2011.04429.x] [Cited by in Crossref: 164] [Cited by in F6Publishing: 125] [Article Influence: 16.4] [Reference Citation Analysis]
54 Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, Tripodi A, Trotter JF, Valla D, Porte RJ. Hemostasis and thrombosis in patients with liver disease: The ups and downs. Journal of Hepatology 2010;53:362-71. [DOI: 10.1016/j.jhep.2010.01.042] [Cited by in Crossref: 242] [Cited by in F6Publishing: 176] [Article Influence: 22.0] [Reference Citation Analysis]
55 Chen SZ, Yuan J, Deng M, Wei J, Zhou J, Wáng YX. Chemical exchange saturation transfer (CEST) MR technique for in-vivo liver imaging at 3.0 tesla. Eur Radiol 2016;26:1792-800. [PMID: 26334509 DOI: 10.1007/s00330-015-3972-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
56 McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int. 2018;12:11-23. [PMID: 29075990 DOI: 10.1007/s12072-017-9826-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
57 Fortea JI, Zipprich A, Fernandez-mena C, Puerto M, Bosoi CR, Almagro J, Hollenbach M, Bañares J, Rodríguez-sánchez B, Cercenado E, Clément M, Rose CF, Bañares R, Vaquero J, Ripoll C, Tacke F. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver Int 2018;38:102-12. [DOI: 10.1111/liv.13510] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
58 Faccia M, Ainora ME, Ponziani FR, Riccardi L, Garcovich M, Gasbarrini A, Pompili M, Zocco MA. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J Gastroenterol. 2019;25:4437-4451. [PMID: 31496623 DOI: 10.3748/wjg.v25.i31.4437] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
59 Tzeng JI, Chen MF, Chung HH, Cheng JT. Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride. Phytother Res. 2013;27:1023-1028. [PMID: 22933420 DOI: 10.1002/ptr.4829] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
60 Yan Y, Guan C, Du S, Zhu W, Ji Y, Su N, Mei X, He D, Lu Y, Zhang C, Xing XH. Effects of Enzymatically Depolymerized Low Molecular Weight Heparins on CCl4-Induced Liver Fibrosis. Front Pharmacol. 2017;8:514. [PMID: 28871223 DOI: 10.3389/fphar.2017.00514] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
61 Seijo S, Garcia-Pagan JC. Anticoagulation in cirrhosis: ready … set … wait! Hepatology 2013;58:1175-6. [PMID: 23703896 DOI: 10.1002/hep.26503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Dong MX, Jia Y, Zhang YB, Li CC, Geng YT, Zhou L, Li XY, Liu JC, Niu YC. Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. World J Gastroenterol. 2009;15:4753-4762. [PMID: 19824107 DOI: 10.3748/wjg.15.4753] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
63 Hiyoshi M, Konishi H, Uemura H, Matsuzaki H, Tsukamoto H, Sugimoto R, Takeda H, Dakeshita S, Kitayama A, Takami H, Sawachika F, Kido H, Arisawa K. d-Dopachrome tautomerase is a candidate for key proteins to protect the rat liver damaged by carbon tetrachloride. Toxicology 2009;255:6-14. [DOI: 10.1016/j.tox.2008.09.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]